Dr. Lal Pathlabs | Business Upturn

Latest Articles

Dr. Lal PathLabs to acquire multi-unit property in New Delhi for Rs 74.51 crore

Corporates · Sep 24, 2025

blank

Dr. Lal PathLabs becomes first in India to adopt AI-based module for cancer lymph node metastasis detection

Corporates · Aug 20, 2025

blank

Dr. Lal PathLabs boots genomics capabilities with Illumina’s NovaSeq™ X Series

Corporates · Jun 25, 2025

blank

Dr. Lal PathLabs shares jump 8% from day low as Q4 revenue rises 10.48% YoY to 602.6 crore

Stock Market · Apr 25, 2025

blank

Dr. Lal PathLabs launch South Asia’s first advanced test for Amyloidosis

Corporates · Apr 15, 2025

blank

Dr. Lal PathLabs Q3 FY25 Results: Revenue rises 11% YoY to Rs 622 crore, Net Profit up 19% YoY

Corporates · Jan 30, 2025

By Aditya Bhagchandani

blank

Dr. Lal Pathlabs stock surges nearly 3% as CLSA upgrade to “Outperform” rating with target price of Rs 3,240

Stock Market · Jan 23, 2025